Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Bio-Rad Introduces New Bio-Plex Pro™ RBM Kidney Toxicity Panels

Published: Thursday, March 14, 2013
Last Updated: Thursday, March 14, 2013
Bookmark and Share
The Bio-Plex Pro™ RBM human, rat, and canine kidney toxicity panels enable early detection and characterization of kidney toxicity and injury during drug development.

Bio-Rad Laboratories, Inc. has announced the launch of its new Bio-Plex Pro RBM human, rat, and canine kidney toxicity panels at the 2013 Society of Toxicology (SOT) annual meeting in San Antonio, TX, March 10-14.

Developed through a partnership with Myriad RBM, Inc., the multiplex immunoassays comprise a set of biomarkers that addresses the need for early detection and characterization of kidney toxicity and injury during drug development.

Acute kidney injury (AKI) is a potentially deadly condition frequently caused by kidney damage due to drug exposure, trauma, or blood loss during a medical procedure.

In contrast, chronic kidney injury (CKI) results from long-term diseases such as diabetes, high blood pressure, or an inherited syndrome.

Protein biomarkers found in urine can signal early signs of kidney toxicity and injury and may provide additional information about the location and severity of damage.

The Bio-Plex Pro RBM assays enable the detection of multiple biomarkers in a single sample, which may reveal damage within hours of kidney injury.

This early detection will allow for more efficient drug testing in both preclinical and clinical research settings.

“The decades-old current clinical tests are not able to detect damage early enough, as evidenced by the fact that two-thirds of the kidney may be irreparably damaged once the traditional biomarkers become elevated,” said Dr. Dominic Eisinger, director of strategic development for Myriad RBM.

Dr. Eisinger continued, “The Bio-Plex Pro RBM panels encompass the most sensitive early markers of kidney injury for preclinical and clinical studies.”

The toxicity panels contain six of the seven markers approved by the FDA and EMEA for use in preclinical kidney toxicity assessment.

Included in these panels are several other markers relevant to kidney toxicity and damage research. The assays are offered as kits that include everything needed to run the assay.

“The Bio-Plex Pro RBM kidney toxicity assays will allow preclinical researchers to monitor biomarker profiles that may predict drug toxicity in the clinic,” said Chris Linnevers, Bio-Rad’s Bio-Plex global product manager.

Linnevers continued, “They also enable clinical researchers to monitor both disease progression and kidney injury during drug trials, which ultimately leads to better-optimized treatment and improved patient care.”

Dr. Eisinger will give a talk on the new assays at the SOT annual meeting. His talk, “Multiplex detection of drug-induced kidney toxicity with new Bio-Plex Pro RBM assays,” will review the need for sensitive and robust assays to evaluate and diagnose kidney injury.

Investigators involved in preclinical and clinical studies of drug safety will learn about the analytical validation of the kits, including their performance in kidney injury studies.

Additional benefits of the Bio-Plex Pro RBM assays include:
• High performance - offer robust quantification of multiple proteins in human, rat, and canine urine samples
• Consistent results - optimized for high precision and lot-to-lot reproducibility of sample measurements
• Simple workflow - formatted on magnetic beads for simplified plate processing and rapid results

The Bio-Plex Pro RBM kidney toxicity panels are compatible with Bio-Plex® MAGPIX™ instruments and Bio-Plex 100/200 and 3D instruments as well as all Luminex platforms and software.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Researchers Develop Rapid, Cost-Effective Early Detection Method for Organ Transplant Injury
Chronix Biomedical and transplant expert Prof. Oellerich use Droplet Digital™ PCR to quantify early rejection biomarker.
Thursday, August 29, 2013
New Biomarker Could Reveal Alzheimer's Disease Years Before Onset
A new study has reported the identification of what may be the earliest known biomarker associated with the risk of developing Alzheimer's disease (AD).
Wednesday, August 14, 2013
Bio-Rad and Myriad RBM Partner to Develop Immunoassay Kits
Partnership to commercialize multiplex biomarker kits for life science research.
Wednesday, August 01, 2012
Bio-Rad Introduces new Pro-Human Diabetes Assay Panel
The Company has launched new Bio-Plex Pro™ Human Diabetes Assay Panels for its Bio-Plex® suspension array system.
Tuesday, June 24, 2008
Bio-Rad Announces Web Seminar Series
Web seminar series area includes Spectroscopy, Chromatography, ADME/Tox and Metabolomics.
Friday, May 05, 2006
Scientific News
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Doubling Down on Dengue
HMS researchers have discovered two ways a compound blocks dengue virus.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
AstraZeneca to Sequence 2 Million Genomes in Search for New Drugs
Company launches integrated genomics approach which aims to transform drug discovery and development.
Unique Model for Studying ALS
Unique mouse model will allow researchers to better study the genetic origins and potential treatments of ALS.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Biomarkers for Profiling Prostate Cancer Patients
Exiqon A/S has announced the publication of validation of prognostic microRNA biomarkers for the aggressiveness of prostate cancer in independent cohorts.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!